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Introduction: We performed a chart review study in our castration-resistant prostate
cancer (CRPC) patients who received Abiraterone acetate (AA) treatment after docetaxel
and identified clinical markers which can predict treatment outcome.
Materials and Methods: From 2012 to 2016, 64 patients who received docetaxel after
CRPC followed by AA treatment were included. Clinical parameters were recorded and
analysis was performed to identify associations between pre-treatment variables and
treatment outcome.
Results: Thirty three patients (51.6%) achieved a decrease in PSA of 50%. The
median PSA progression-free survival and overall survival in the total cohort of 64
patients were 6.6 and 24 months, respectively. Adverse events (AEs) in all grades
developed in 35.9% (23/64) patients and mostly were grade 1 or 2. The most
common AEs were gastric upset, hypokalemia and elevated liver function tests. Of
the eight variables analyzed, first line androgen deprivation therapy (ADT) duration
showed positive association to progression free survival (HR 0.98, 95% CI [0.96–0.99],
p = 0.012) and overall survival (HR 0.97, 95% CI [0.94–0.99], p = 0.019). Pre-AA PSA
and PSA progression ratio showed negative association only to progression free survival
(HR 1.0, 95% CI [1.000–1.002], p = 0.025, HR 1.01, 95% CI [1.00–1.01], p < 0.001,
respectively).
Conclusion: First line ADT duration was positively associated with AA treatment efficacy
in progression free survival and overall survival. It can be used as a pre-treatment
predictor.
Keywords: abiraterone acetate, androgen deprivation therapy, castration-resistant prostate cancer, docetaxel,
PSA
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INTRODUCTION
Abiraterone acetate (AA) has been shown to be effective in
prolonging progression-free survival and overall survival in
metastatic castration-resistant prostate cancer (MCRPC) after
docetaxel chemotherapy (de Bono et al., 2011). Although the
recent COU-AA-302 (Cougar Biotechnology, AA) study showed
a clinical benefit of AA in a chemo-naïve setting, it still have
more clinical applications using the post-chemotherapy model
for advanced prostate cancer patients in Asian countries. In
the subgroup analysis of the COU-AA-301 trial, AA showed
an equivalent efficacy in the Asian group compared with data
from Western countries with progression-free survival (Fizazi
et al., 2012; Kwak et al., 2014). Various parameters were used
for prediction of patient outcome during AA treatment, but still
controversial (Azad et al., 2015; Houede et al., 2015; Xu et al.,
2015; Bellmunt et al., 2016; Chi et al., 2016; Facchini et al.,
2016; Rescigno et al., 2016). Herein, we conducted a clinical
investigation of AA in CRPC patients after chemotherapy and
validated several clinical factors correlated with progression-free
survival and overall survival before AA treatment.
MATERIALS AND METHODS
Patients
This was a retrospective chart-review study which analyzed
metastatic castration prostate cancer patients after chemotherapy
using AA between 2012 and 2016. Of the 71 consecutive
patients, 7 were excluded because of incomplete data or loss
of follow-up and were also excluded. All included patients
received informed consent before treatment according to the
certification of the institute review board of Taichung Veterans
General Hospital, number CE13240A-2. The rest 64 patients
all had bone metastases and were included in this analysis.
All patients received AA 1000 mg with prednisolone 5 mg or
10 mg per day. Patients received proper pain control with opioid
medication or palliative radiation therapy according to clinical
requirements.
Study Assessment
The primary patient characteristics were age at start of AA
treatment, serum PSA level at MCRPC, PSA at chemotherapy,
PSA at AA treatment, first-line chemotherapy cycles, second-line
cycles, first-line androgen deprivation therapy (ADT) duration,
chemotherapy duration, PSA progression velocity before AA,
PSA progression ratio before AA treatment, follow-up duration,
progression-free survival of AA treatment, overall survival of
AA treatment and survival status. Maximal effect period was
recorded as the time period required to the lowest PSA level
after AA treatment. The adverse events (AEs) developed during
treatment were also recorded.
The first-line ADT duration was defined as the months
between the date of ADT beginning and the date of CRPC.
First-line ADT included surgical castration (orchiectomy) or
medical castration using LH-RH agonists or antagonists. The
chemotherapy cycles were defined according to the standard
3-week docetaxel treatment. In our practice, 2-week and 4-
week courses of chemotherapy were performed. We transferred
the 2-week cycles into standard 3-week cycle counts. PSA
progression was defined according to the Prostate Cancer
Working Group second publication (PCWG2) criteria (Scher
et al., 2008). Some patients also received bone scan and evaluation
symptoms to better define their progression. Although the
clinical management did not completely match the definition
criteria, such as delayed or early chemotherapy at the time
of PSA progression, we still recorded the date of treatment.
Chemotherapy duration was defined as the months between the
date of AA treatment beginning and the date of chemotherapy
beginning. PSA progression velocity before AA was defined
as the PSA change between the pre-AA treatment and the
CRPC divided by the time interval. PSA progression ratio was
defined as PSA before AA treatment divided by the CRPC PSA
level.
Statistical Analysis
The differences between continuous values were analyzed by
Mann–WhitneyU test and Fisher’s exact test t-test for continuous
variables. χ2 test was used for categorical variables. The
progression-free survival and overall survival curves were plotted
using the Kaplan–Meier method with statistical significance
examined by the log-rank test. Univariate and multivariate Cox
hazard regression was used to estimate the hazard ratio (HR) and
95% confidence interval (CI) for association between variables
and progression-free and overall survival. All statistical analyses
were performed using SAS software version 9.2 (SAS Institute,
Inc., Cary, NC, USA). A p-value of < 0.05 was considered
statistically significant.
RESULT
Thirty-three patients (51.6%, 33/64) met the criteria of PSA
decline greater than 50% after AA treatment. Table 1 shows the
basic characteristics among all 64 patients. During the median
7.9 months follow-up period, 43 patients (67.2%) were still
alive. The median first line ADT duration was 26.9 months
and the median fist line chemotherapy used was seven cycles.
Twenty-five patients (39.1%) received second line chemotherapy
with cabazitaxel with a median of four cycles. The overall
chemotherapy duration before AA treatment was 17.1 months.
The median progression free survival expected using the Log-
rank test was 6.6 months and the overall survival was 24 months
(Figures 1 and 2).
Table 2 shows the development of AEs during AA treatment.
The development percentage of grade 1/2 and grade 3/4 AE was
31.3% (20/64) and 4.7% (3/64), respectively. However, one case
of hyperkalemia developed in the PSA non-responder group
and resulted in patient death. Two patients experienced elevated
glutamate oxaloacetate transaminase (GOP) and glutamate
pyruvate transaminase (GPT). They received temporary
suspension of AA; one of them recovered after 1 week and was
kept on treatment without tapering dosage and the other had
PSA progression.
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TABLE 1 | Basic characteristics of patients receiving Abiraterone acetate
treatment.
Median Range
Age at AA treatment (years; n = 64) 72 49–89
Received radical prostatectomy (n, %) 15 23.4%
Start 1st line ADT age (months; n = 64) 66.0 46–87
1st line ADT duration (months; n = 63) 26.9 2.3–144.5
CRPC PSA (n = 63) 5.3 2–354
1st line chemo cycles (n = 63) 7.0 1–33
2nd line chemo cycles (n = 25) 4.0 3–12
Chemotherapy period (months; n = 63) 17.1 2.7–71
Pre-AA PSA (n = 64) 42.7 4–1941
PSA response (n, %) 33 51.6%
PSA decline % (n = 64) 80.3 −269–99.9
Total follow-up period (months; n = 64) 7.9 0.9–46.5
Maximal effect period (months; n = 37) 3.6 0.5–11.7
Progress-free survival (months; n = 64) 4.1 0.8–25.2
PSA velocity (PSA/months; n = 63) 1.0 −23.2–78.1




AA, abiraterone acetate; ADT, androgen deprivation therapy; CRPC, castration-
resistant prostate cancer. PSA decline, (Pre-AA PSA subtract Lowest PSA after AA)
divided by Pre-AA PSA. PSA velocity before AA, (Pre-AA PSA subtract CRPC PSA)
divided by (Date start AA subtract Date CRPC). PSA ratio, Pre-AA PSA divided by
CRPC PSA.
FIGURE 1 | Progression-free survival in total 64 patients.
In univariate Cox regression analysis, first-line ADT duration
showed a positive association to better progression free survival;
pre-AA PSA, and PSA progression ratio showed a negative
association to longer progression free survival. After adjustment,
all three factors were considered predictors of PSA progression
FIGURE 2 | Overall survival in total 64 patients.
TABLE 2 | Adverse events during abiraterone acetate treatment.
Patients (n = 64)
Grade 1/2 Grade 3/4
Subjects with AE, n (%) 20 (31.3) 3 (4.7)
General AE, n (%)
Diarrhea 1 (1.6) 0
Hypokalemia 3 (4.7) 0
Hyperkalemia 1 (1.6) 1 (1.6)
Fatigue 2 (3.1) 0
Vertigo 1 (1.6) 0
Stasis dermatitis 2 (3.1) 0
Leg edema 4 (6.3) 0
Puffing face 1 (1.6) 0
Gastric upset 4 (6.3) 0
Elevated liver function 1 (1.6) 2 (3.1)
before AA treatment (Table 3). In the analysis of overall survival,
only first line ADT duration reached the statistical significance
(p= 0.019) (Table 4).
DISCUSSION
Our study provided the evidence that clinical, non-laboratory
parameters can also predict patient outcome using AA treatment
in post-docetaxel MCRPC. Several clinical factors had been used
as outcome predictors. Chi et al. (2016) used database from
COU-AA-301 study and found serum lactate dehydrogenase
(LDH), Eastern Cooperative Oncology Group Performance
Status (ECOG PS), liver metastases, serum albumin, serum
alkaline phosphatase (ALP) and first line ADT duration could act
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TABLE 3 | Predictive variables of progression-free survival.
Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Age at AA treatment 0.99 (0.95–1.03) 0.476
1st line ADT duration (months) 0.98 (0.96–0.99) 0.011∗ 0.98 (0.96–0.99) 0.012∗a
CRPC PSA 1.00 (1.00–1.01) 0.163
Pre-chemo PSA 1.00 (1.00–1.00) 0.544
1st line chemo cycles 0.99 (0.94–1.03) 0.597
Pre-AA PSA 1.00 (1.00–1.00) 0.023∗ 1.00 (1.000–1.002) 0.025∗a
PSA velocity before AA (PSA/month) 1.01 (1.00–1.02) 0.138
PSA progression ratio 1.00 (1.00–1.01) 0.001∗ 1.01 (1.00–1.01) <0.001∗b
Cox regression. HR, hazard ratio. aAdjusted for 1st line ADT duration (months), Pre-AA PSA, bAdjusted for 1st line ADT duration (months), PSA progression ratio.
∗P < 0.05.
TABLE 4 | Predictive variables of overall survival.
Univariate analysis
HR 95% CI p-value
Age at AA treatment 1.01 (0.96–1.07) 0.695
1st line ADT duration (months) 0.97 (0.94–0.99) 0.019∗
CRPC PSA 1.00 (0.99–1.01) 0.924
PRE-chemo PSA 1.00 (1.00–1.01) 0.428
1st line chemo cycles 0.96 (0.89–1.03) 0.289
Chemo period (month) 0.98 (0.94–1.02) 0.255
Pre-AA PSA 1.00 (1.00–1.00) 0.186
PSA velocity before AA (PSA/month) 1.01 (1.00–1.03) 0.069
PSA progression ratio 1.00 (1.00–1.01) 0.270
Cox regression. HR, hazard ratio. aAdjusted for 1st line ADT duration
(month).∗p < 0.05.
as a cumulative scoring system to predict AA treatment efficacy.
Our data corresponded to their finding on the ADT treatment
duration. However, lack of most of lab blood tests or image
study results makes our finding limited. Facchini et al. (2016)
reported early PSA response could predict the overall survival
after AA treatment which was a post-treatment prediction.
Our study is the first to show pre-treatment clinical markers
such as first-line ADT duration, pre-AA PSA level, and PSA
progression ratio may correspond to progression-free survival
and may serve as a simpler tool for predicting AA treatment
outcome.
Molecular factors such as androgen-receptor splice variant
seven messenger RNA (AR-V7) has been well studied in the
prediction of the efficacy of second-line hormone therapy,
especially AA and enzalutamide (Antonarakis et al., 2014).
AR-V7 not only explained the possible drug-resistant
mechanism, it may have value as a predictive tool before
second-line hormone therapy.
The overall PSA response rate was 51.6% (33/64) in our study
which was better than the 29.5% response rate found in the COU-
AA-301 trial. Our data were similar to the findings of a previous
Korean and Taiwanese small group study which showed a PSA
response rate of 43% (Kwak et al., 2014). However, our results
showed the median PSA progression-free survival was only
6.6 months which was shorter than the duration of 8.5 months in
the COU-AA-301 trial. This is because the definition of treatment
failure in our series was only based on PSA progression.
Interestingly, our median overall survival was 24 months which
was longer than the duration of 15.8 months in the COU-AA-301
trial. This is the result of some patients who experienced longer
overall survival (longest follow-up 46.5 months) in our database
which made survival prediction right shift.
The median time to maximal PSA response was 3.6 months
which implied most patients who were sensitive to AA treatment
would experience early PSA response in about 3 months period.
This finding corresponded to Facchini’s results in the post-
treatment observation. However, one patient did not reach lowest
PSA decline until 9.3 months. This patient did have early PSA
decline about 55% after 6 months, he received prednisolone shift
to dexamethasone and experienced more PSA decline to 90%.
Similar findings were reported by Lorente et al. (2014).
Our data showed most patients tolerated AA well and only
4.7% (3/64) had grade 3/4 AEs. One of them developed severe
hyperkalemia and died of shock. The precise etiology was
unknown but a latent infection which induced septic shock and
acute renal failure was suspected. Some patients developed leg
and facial edema and symptoms similar to metabolic syndrome
in previous reports (Logothetis et al., 2012).
The treatment strategy of MCRPC has been discussed in the
literature in recent years (Sonpavde et al., 2015; van Dodewaard-
de Jong et al., 2015; van Soest et al., 2015). In our study, 29.7%
(19/64) patients received cabazitaxel before AA in the early
period. After AA was insurance reimbursed, no patients received
cabazitaxel before AA. Ten patients received docetaxel after AA
failure which showed no obvious survival benefit as previous
reports (Zhang et al., 2015).
There were several limitations in our study. First, this is a
retrospective chart review study. PSA check-up schedules and
many variables were not well controlled. Second, PSA was
the only parameter to define treatment outcome in our study.
It is now considered PCWG3 consensus as a recommended
evaluations in CRPC studies (Scher et al., 2016). There would
be outcome variations in such different standards. Third, six
patients in the PSA responder group received prednisolone
shift to dexamethasone after PSA mild elevation. All of them
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experienced PSA decline after shifting and it was regarded as
treatment continuing in our study. Although this design might
influence progression free survival, there should be no differences
in the overall survival comparison. Fourth, our sample size was
too small and the HR seemed no such great impact even reaching
statistical significance.
CONCLUSION
Our real-world patient data showed that pre-treatment predictors
of AA in PSA progression-free survival included first-line ADT
duration, pre-AA PSA, and PSA progression ratio. For overall
survival, first-line ADT duration can also serve as a pre-treatment
predictor. PSA response itself can be applied as post-treatment
predictors for PSA progression-free survival and overall survival
after prescription.
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